Recent Updates
Recently added Catalysts

risperidone; quetiapine

Phase 3

Bipolar Disorder | Small molecule | Psychiatry |Johnson & Johnson|Last Updated: May 24, 2011

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindUNCONTROLLED
Total Trials1
Total Enrollment30

FDA Designations

No designations recorded

Clinical trial landscape

risperidone; quetiapine · 1 trial · 1 indication

Phase 3 1
NCT00097032Study Measuring Differences in Cognition Due to Sedative Effects of Risperidone and Quetiapine in Stable Bipolar I OutpatientsBipolar Disorder
COMPLETED30 Analytics
PHASE3COMPLETED
Study Measuring Differences in Cognition Due to Sedative Effects of Risperidone and Quetiapine in Stable Bipolar I Outpatients
Bipolar Disorder
NCT0009703230
Unlock trial analytics

Study Endpoints

Primary Endpoints

To compare the treatment effects of risperidone and quetiapine on cognitive function due to sedation

Secondary Endpoints

To assess the association between subjective experience of sedation and cognitive function
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelCROSSOVER

Interventions

NameTypeDescription
risperidone; quetiapineDRUG -
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 45 Years
SexALL
Healthy VolunteersNo

Inclusion Criteria: * Subjects with bipolar I disorder in partial or full remission and deemed clinically stable Exclusion Criteria: * Current use of benzodiazepines, prescription or herbal sleep agents * Use of antihistamines * Use of antipsychotic medications in the past 6 months * Pregnant/bre...

Unlock Eligibility Criteria

Competitive Landscape -Bipolar Disorder 20 trials

CompanyTickerTrialsLead PhaseDrugs
Bristol-Myers Squibb CompanyBMY4PHASE3KarXT
AbbVie, Inc.ABBV3PHASE3Cariprazine
Alkermes Public Limited CompanyALKS2PHASE3OLZ/SAM
Xenon Pharmaceuticals Inc.XENE2PHASE3Azetukalner
Eli Lilly and CompanyLLY1PHASE2Brenipatide
Rapport Therapeutics, Inc.RAPP1PHASE2RAP-219
Neurocrine Biosciences, Inc.NBIX1PHASE2NBI-1117568
Alto Neuroscience, Inc.ANRO1PHASE2ALTO-100
LB Pharmaceuticals, Inc.LBRX1PHASE2LB-102
BioXcel Therapeutics, Inc.BTAI1PHASE1BXCL501 80 Micrograms, BXCL501 120 Micrograms, BXCL501 60 Micrograms
Alzamend Neuro, Inc.ALZN1PHASE1AL001, Lithium carbonate
Unlock Competitive Intelligence